P53 as a prognostic marker for bladder cancer: A meta-analysis and review

Lancet Oncology

Volumn 6, Issue 9, 2005, Pages 678-686

  Malats, Núria ^a   Bustos, Aurelia ^b   Nascimento, Cristiane M ^a   Fernandez, Francisco ^a   Rivas, Manuel ^c   Puente, Diana ^a   Kogevinas, Manolis ^a   Real, Francisco X ^a,d  

^a INST MUNIC D INVESTIGACIO MEDICA   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^c HOSPITAL DE CABUEÑES   (Spain)

^d UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PROTEIN P53;

ADULT; BLADDER CANCER; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CLINICAL TRIAL; DISEASE COURSE; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; INFORMATION PROCESSING; MALE; META ANALYSIS; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PUBLICATION; REGRESSION ANALYSIS; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW;

EID: 24044554230     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(05)70315-6     Document Type: Article

References (74)

1. F Millan-Rodriguez G Chechile-Toniolo J Salvador-Bayarri et al. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence J Urol 164 2000 680-684
2. F Millan-Rodriguez G Chechile-Toniolo J Salvador-Bayarri et al. Multivariate analysis of the prognostic factors of primary superficial bladder cancer J Urol 163 2000 73-78
3. P Carroll D Raghavan J Stein The treatment of bladder cancer - stage by stage. American Urology Association Course Book 2001 American Urology Association Anaheim
4. MA Knowles What we could do now: Molecular pathology of bladder cancer Mol Pathol 54 2001 215-221
5. SM Donat Evaluation and follow-up strategies for superficial bladder cancer Urol Clin North Am 30 2003 765-776
6. JP Stein G Lieskovsky R Cote et al. Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1054 patients J Clin Oncol 19 2001 666-675
7. B Vogelstein D Lane AJ Levine Surfing the p53 network Nature 408 2000 307-310
8. P Hainaut M Hollstein p53 and human cancer: The first ten thousand mutations Adv Cancer Res 77 2000 81-137
9. JP Stein GD Grossfeld DA Ginsberg et al. Prognostic markers in bladder cancer: A contemporary review of the literature J Urol 160 1998 645-659
10. BJ Schmitz-Drager PJ Goebell T Ebert et al. p53 immunohistochemistry as a prognostic marker in bladder cancer. Playground for urology scientists? Eur Urol 38 2000 691-699
11. D Esrig D Elmajian S Groshen et al. Accumulation of nuclear p53 and tumor progression in bladder cancer N Engl J Med 331 1994 1259-1264
12. AR Zlotta CC Schulman Biological markers in superficial bladder tumors and their prognostic significance Urol Clin North Am 27 2000 179-189
13. AF Olumi A critical analysis of the use of p53 as a marker for management of bladder cancer Urol Clin North Am 27 2000 75-82
14. JR Masters UD Vani KM Grigor et al. Can p53 staining be used to identify patients with aggressive superficial bladder cancer? J Pathol 200 2003 74-81
15. PJ Goebell S Groshen BJ Schmitz-Dräger et al. The international bladder cancer bank - proposal for a new study concept Urol Oncol 4 2004 277-284
16. T Soussi C Beroud Assessing TP53 status in human tumours to evaluate clinical outcome Nat Rev Cancer 1 2001 233-240
17. PK Lipponen Over-expression of p53 nuclear oncoprotein in transitional-cell bladder cancer and its prognostic value Int J Cancer 53 1993 365-370
18. DJ Thomas MC Robinson R Charlton et al. P53 expression, ploidy and progression in pT1 transitional cell carcinoma of the bladder Br J Urol 73 1994 533-537
19. D Esrig D Elmajian S Groshen et al. Accumulation of nuclear p53 and tumor progression in bladder cancer N Engl J Med 331 1994 1259-1264
20. AS Sarkis G Dalbagni C Cordon-Cardo et al. Association of P53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder J Urol 152 1994 388-392
21. JA Vet PP Bringuier PJ Poddighe et al. p53 mutations have no additional prognostic value over stage in bladder cancer Br J Cancer 70 1994 496-500
22. S Jahnson B Risberg MG Karlsson et al. p53 and Rb immunostaining in locally advanced bladder cancer: Relation to prognostic variables and predictive value for the local response to radical radiotherapy Eur Urol 28 1995 135-142
23. AS Sarkis DF Bajorin VE Reuter et al. Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC J Clin Oncol 13 1995 1384-1390
24. SH Glick LP Howell RW White Relationship of p53 and bcl-2 to prognosis in muscle-invasive transitional cell carcinoma of the bladder J Urol 155 1996 1754-1757
25. L Lacombe G Dalbagni ZF Zhang et al. Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after bacillus Calmette-Guerin therapy: Correlation to clinical outcome J Clin Oncol 14 1996 2646-2652
26. H Ovesen T Horn K Steven Long-term efficacy of intravesical bacillus Calmette-Guerin for carcinoma in situ: Relationship of progression to histological response and p53 nuclear accumulation J Urol 157 1997 1655-1659
27. Z Popov A Hoznek M Colombel et al. The prognostic value of p53 nuclear overexpression and MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder Cancer 80 1997 1472-1481
28. R Abdel-Fattah C Challen TR Griffiths et al. Alterations of TP53 in microdissected transitional cell carcinoma of the human urinary bladder: high frequency of TP53 accumulation in the absence of detected mutations is associated with poor prognosis Br J Cancer 77 1998 2230-2238
29. S Jahnson MG Karlsson Predictive value of p53 and pRb immunostaining in locally advanced bladder cancer treated with cystectomy J Urol 160 1998 1291-1296
30. G Kong KY Shin YH Oh et al. Bcl-2 and p53 expressions in invasive bladder cancers Acta Oncol 37 1998 715-720
31. L Nakopoulou C Vourlakou A Zervas et al. The prevalence of bcl-2, p53, and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates Hum Pathol 29 1998 146-154
32. GA Niehans RA Kratzke MK Froberg et al. G1 checkpoint protein and p53 abnormalities occur in most invasive transitional cell carcinomas of the urinary bladder Br J Cancer 80 1999 1175-1184
33. D Plastiras G Moutzouris C Barbatis et al. Can p53 nuclear over-expression, Bcl-2 accumulation and PCNA status be of prognostic significance in high-risk superficial and invasive bladder tumours? Eur J Surg Oncol 25 1999 61-65
34. KN Qureshi TR Griffiths MC Robinson et al. TP53 accumulation predicts improved survival in patients resistant to systemic cisplatin-based chemotherapy for muscle-invasive bladder cancer Clin Cancer Res 5 1999 3500-3507
35. M Sanchez-Carbayo MT Chulia M Niveiro et al. Autoantibodies against P53 protein in patients with transitional cell carcinoma of the bladder Anticancer Res 19 1999 3531-3537
36. H Shiina M Igawa K Shigeno et al. Clinical significance of MDM2 and p53 expression in bladder cancer: A comparison with cell proliferation and apoptosis Oncology 56 1999 239-247
37. JP Gao T Uchida C Wang et al. Relationship between p53 gene mutation and protein expression: Clinical significance in transitional cell carcinoma of the bladder Int J Oncol 16 2000 469-475
38. R Tiguert FJ Bianco Jr. P Oskanian et al. Structural alteration of p53 protein in patients with muscle invasive bladder transitional cell carcinoma J Urol 166 2001 2155-2160
39. H Tokunaga SF Shariat AE Green et al. Correlation of immunohistochemical molecular staging of bladder biopsies and radical cystectomy specimens Int J Radiat Oncol Biol Phys 51 2001 16-22
40. T Uchida S Minei JP Gao et al. Clinical significance of p53, MDM2 and bcl-2 expression in transitional cell carcinoma of the bladder Oncol Rep 9 2002 253-259
41. SA Hussain R Ganesan L Hiller et al. BCL2 expression predicts survival in patients receiving synchronous chemoradiotherapy in advanced transitional cell carcinoma of the bladder Oncol Rep 10 2003 571-576
42. SA Hussain R Ganesan L Hiller et al. Proapoptotic genes BAX and CD40L are predictors of survival in transitional cell carcinoma of the bladder Br J Cancer 88 2003 586-592
43. TA Ong SC Peh KS Goh P53 protein expression in transitional cell carcinoma of the bladder - experience of the University of Malaya Medical Centre Asian J Surg 26 2003 31-36
44. L Santos T Amaro C Costa Ki-67 index enhances the prognostic accuracy of the urothelial superficial bladder carcinoma risk group classification Int J Cancer 105 2003 267-272
45. T Liukkonen P Rajala M Raitanen et al. for the Finnbladder Group Prognostic value of MIB-1 score, p53, EGFr, mitotic index and papillary status in primary superficial (Stage pTa/T1) bladder cancer: A prospective comparative study Eur Urol 36 1999 393-400
46. C Pfister L Moore P Allard et al. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence Clin Cancer Res 5 1999 4079-4084
47. Y Yan GL Andriole PA Humphrey AS Kibel Patterns of multiple recurrences of superficial (Ta/T1) transitional cell carcinoma of bladder and effects of clinicopathologic and biochemical factors Cancer 95 2002 1239-1246
48. A Pycha C Mian B Posch et al. Numerical chromosomal aberrations in muscle invasive squamous cell and transitional cell cancer of the urinary bladder: An alternative to classic prognostic indicators? Urology 53 1999 1005-1010
49. MG Bol JP Baak S Rep et al. Prognostic value of proliferative activity and nuclear morphometry for progression in TaT1 urothelial cell carcinomas of the urinary bladder Urology 60 2002 1124-1130
50. PU Malmstrom H Wijkstrom C Lundholm et al. for the Swedish-Norwegian Bladder Cancer Study Group 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma J Urol 161 1999 1124-1127
51. MA Underwood J Reeves G Smith et al. Overexpression of p53 protein and its significance for recurrent progressive bladder tumors Br J Urol 77 1996 659-666
52. E Lee I Park C Lee Prognostic markers of intravesical bacillus Calmette-Guerin therapy for multiple, high-grade, stage T1 bladder cancers Int J Urol 4 1997 552-556
53. JP Crew T O'Brien M Bradburn et al. Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer Cancer Res 57 1997 5281-5285
54. JP Stein DA Ginsberg GD Grossfeld et al. Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer J Natl Cancer Inst 90 1998 1072-1079
55. N Fleshner L Kapusta D Ezer et al. p53 nuclear accumulation is not associated with decreased disease-free survival in patients with node positive transitional cell carcinoma of the bladder J Urol 164 2000 1177-1182
56. S Kruger C Thorns W Stocker et al. Prognostic value of MCM2 immunoreactivity in stage T1 transitional cell carcinoma of the bladder Eur Urol 43 2003 138-145
57. AS Sarkis G Dalbagni C Cordon-Cardo et al. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: A marker for disease progression J Natl Cancer Inst 85 1993 53-59
58. SJ Moreno JA Lopez Garcia Asenjo GE Redondo et al. Usefulness of p53 oncoprotein immunohistochemistry in the follow-up of bladder carcinoma: a 5-year study Arch Esp Urol 52 1999 840-848 (in Spanish)
59. T Morita N Tachikawa T Kumamaru et al. Serum anti-p53 antibodies and p53 protein status in the sera and tumors from bladder cancer patients Eur Urol 37 2000 79-84
60. M Migaldi A Sgambato L Garagnani et al. Loss of p21Waf1 expression is a strong predictor of reduced survival in primary superficial bladder cancers Clin Cancer Res 6 2000 3131-3138
61. X Garcia del Muro A Torregrosa J Munoz et al. Prognostic value of the expression of E-cadherin and beta-catenin in bladder cancer Eur J Cancer 36 2000 357-362
62. ML Lu F Wikman TF Orntoft et al. Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods Clin Cancer Res 8 2002 171-179
63. T Nomura M Nakagawa Y Fujita et al. Clinical significance of thymidylate synthase expression in bladder cancer Int J Urol 9 2002 368-376
64. MS Greenblatt WP Bennett M Hollstein et al. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis Cancer Res 54 1994 4855-4878
65. C Cordon-Cardo G Dalbagni GT Saez et al. p53 mutations in human bladder cancer: Genotypic versus phenotypic patterns Int J Cancer 56 1994 347-353
66. M Li CL Brooks N Kon W Gu A dynamic role of HAUSP in the p53-Mdm2 pathway Mol Cell 13 2004 879-886
67. KT Kelsey T Hirao A Schned et al. A population-based study of immunohistochemical detection of p53 alteration in bladder cancer Br J Cancer 90 2004 1572-1576
68. RC Bast Jr. P Ravdin DF Hayes et al. American Society of Clinical Oncology Tumor Markers Expert Panel. 2000 Update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology J Clin Oncol 19 2001 1865-1878
69. DG Altman B Lausen W Sauerbrei et al. Dangers of using "optimal" cutpoints in the evaluation of prognostic factors J Natl Cancer Inst 86 1994 829-835
70. A Laupacis G Wells WS Richardson et al. for the Evidence-Based Medicine Working Group Users' guides to the medical literature V: How to use an article about prognosis JAMA 272 1994 234-237
71. L Stewart MKB Parmar Meta-analysis of the literature or individual patient data; is there a difference? Lancet 341 1993 418-422
72. RD Riley SA Burchill KR Abrams et al. A systematic review and evaluation of the use of tumor markers in paediatric oncology: Ewing's sarcoma and neuroblastoma Health Technol Assess 7 2003 1-162
73. C Cordon-Cardo p53 and Rb: Simple interesting correlates or tumor markers of clinical predictive nature? J Clin Oncol 22 2004 1-3
74. M Blettner W Sauerbrei B Schlehofer et al. Traditional reviews, meta-analysis and pooled analyses in epidemiology Int J Epidemiol 28 1999 1-9